Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

In her new book, psychiatrist Joanna Moncrieff examines the popular belief that antidepressants "work." Among many other ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Many people with depression and anxiety in the U.S. could benefit from medication but do not receive any treatment, ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Most antidepressants are very effective at reducing the severity of depression. However, many are associated with an infamous side effect: weight gain. Luckily, some antidepressants are less ...